The Chinese biotechnology company believes tFNAs will play an increasingly important role in skin care science.
According to the 2024 Blue Book of Tetrahedral Framework Nucleic Acid, co-authored by Trautec and Frost & Sullivan, tFNAs have significant skin care benefits.
The report said that tFNAs have showed a significant ability to promote cell proliferation, tissue repair and wound healing, while also exhibiting anti-inflammatory effects.
tFNAs also have have antioxidant effects, with a “strong ability” to scavenge reactive oxygen species (ROS).
Furthermore, the report said that tFNA can clear senescent cells by inducing cell apoptosis of the cells.
“Although its molecular weight is very big – round more than 100 kilodalton. But the penetration effect is extremely good, and it usually acts like a carrier to carry drugs into the body,” said Catherine Feng, sales director at Trautec.
With these benefits, Trautec sees significant potential for tFNAs in the rapidly expanding medical device sector.
“Medical device products are much more popular than ever before. These products can be a mask or a cream but are used after things like laser treatments. Many big brands are focusing on medical devices, trying to move from cosmetics to the medical device side with stronger functions. This is a big trend in China and now with more big brands entering this market, we think it has become a global trend,” said Feng.
Feng highlighted the growing popularity of polydeoxyribonucleotide (PDRN) in cosmetics, which became a well-known ingredient after it started appearing in South Korean cosmetic products.
PDRN is a DNA-derived compound extracted from salmon or trout sperm. It is widely used in skin regeneration, wound healing, and anti-ageing treatments.
It is often marketed as a medical-grade skin care ingredient and can be found in injectable skin boosters and high-end cosmeceuticals like serums and creams.
While conventional PDRN comes from an animal source, tFNA is a synthetic biomaterial, making it easier for cosmetic companies to navigate regulatory barriers and enter the market, Feng said.
Filling in the gaps
Trautec specialises in the development of synthetic recombinant human collagen SRHC and has achieved large-scale production of Type I, II, III, and XVII SRHC.
Moving forward, the company is aiming to expand its capabilities beyond collagen and into developing other synthetic proteins.
“Collagen is very significant in our body but there are other proteins like elastin. We want to mimic the whole body’s structure, repair all the proteins, to fil in all the gaps in the body,” said Feng.
